Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBT Margin: 2011-2025

Historic EBT Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -138.85%.

  • Iovance Biotherapeutics' EBT Margin rose 642.00% to -138.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -159.06%, marking a year-over-year increase of 29895.00%. This contributed to the annual value of -228.56% for FY2024, which is 3740945.00% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' EBT Margin is -138.85%, which was up 24.10% from -182.93% recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' EBT Margin peaked at -104.49% during Q4 2024, and registered a low of -44,960.08% during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' EBT Margin had a median value of -278.04% in 2024 and averaged -11,111.63%.
  • Data for Iovance Biotherapeutics' EBT Margin shows a peak YoY surged of 4,464,324bps (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' EBT Margin (Quarterly) stood at -24,509.96% in 2023, then surged by 2,440,547bps to -104.49% in 2024, then surged by 642bps to -138.85% in 2025.
  • Its EBT Margin was -138.85% in Q3 2025, compared to -182.93% in Q2 2025 and -239.24% in Q1 2025.